Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPROtm (amivantamab and hyaluronidase-lpuj). When ...
Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO FDA approval to deliver the simplest and fastest ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果